- Home
- UROY vs INBX Comparison
UROY vs INBX Comparison
Compare UROY & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UROY
- INBX
- Stock Information
- Founded
- UROY 2017
- INBX 2010
- Country
- UROY Canada
- INBX United States
- Employees
- UROY N/A
- INBX N/A
- Industry
- UROY
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- UROY
- INBX Health Care
- Exchange
- UROY Nasdaq
- INBX Nasdaq
- Market Cap
- UROY 239.1M
- INBX 198.2M
- IPO Year
- UROY N/A
- INBX 2020
- Fundamental
- Price
- UROY $1.60
- INBX $12.87
- Analyst Decision
- UROY Strong Buy
- INBX Hold
- Analyst Count
- UROY 2
- INBX 1
- Target Price
- UROY $5.60
- INBX N/A
- AVG Volume (30 Days)
- UROY 2.6M
- INBX 112.6K
- Earning Date
- UROY 03-06-2025
- INBX 05-08-2025
- Dividend Yield
- UROY N/A
- INBX 6.03%
- EPS Growth
- UROY N/A
- INBX N/A
- EPS
- UROY N/A
- INBX 112.62
- Revenue
- UROY $15,984,827.00
- INBX $200,000.00
- Revenue This Year
- UROY N/A
- INBX N/A
- Revenue Next Year
- UROY $6.55
- INBX N/A
- P/E Ratio
- UROY N/A
- INBX $0.13
- Revenue Growth
- UROY N/A
- INBX N/A
- 52 Week Low
- UROY $1.57
- INBX $10.80
- 52 Week High
- UROY $3.12
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- UROY 32.05
- INBX 47.34
- Support Level
- UROY $1.72
- INBX $13.51
- Resistance Level
- UROY $1.85
- INBX $14.16
- Average True Range (ATR)
- UROY 0.08
- INBX 0.69
- MACD
- UROY -0.00
- INBX -0.10
- Stochastic Oscillator
- UROY 3.61
- INBX 29.65
About UROY Uranium Royalty Corp.
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is the investment in a portfolio of uranium interests.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.